Home > Books > Medicine > Cardiology > DES with bioabsorbable polymers antiplatet therapy and stent thrombosis

DES with bioabsorbable polymers antiplatet therapy and stent thrombosis

First edition (2012)
DANZI G.B., PISCIONE F.
A volume of 60 pages with 4 b/w and colour figures and 8 tables
Cover: paperback
ISBN-13 978-88-7711-747-2
Language: English

Price: € 20,00  € 17,00 HOW TO ORDER   EMAIL ALERT

 

The aim of this book is to offer an update concerning the use of DES with bioabsorbable polymers and antiplatelet therapy.
Drug eluting stents are complex medical devices comprising several components which must function in synergy to
ensure an optimal result. These generally include the metallic stent platform, a biologically active drug, and a polymer. The
fundamental function of the polymer is to retain and release drug in a controlled fashion and within a predictable time window. Non-resorbable polymers have been incriminated for hypersensitivity reaction, increased vessel wall inflammation,
apoptosis of smooth muscle cells, and induction of stent thrombosis. Because of these potential problems, efforts have been made to attach the drug directly to the stent or to release it via bioabsorbable polymers with reduced surface area trough the use of reservoirs or coating on the abluminal stent surface only. While direct attachment of drugs to the metallic surface with a reproducible controlled release still is difficult to achieve, the bioresorbable coatings, which are well suited to controlled drug release appear as an attractive solution that could potentially decrease the likelihood of late stent thrombosis.
This book is a valuable resource for interventional cardiologists who perform cardiac interventional procedures.
Contents
DRUG ELUTING STENTS WITH BIORESORBABLE POLYMER: THE MENU
THE NOBORI CLINICAL EXPERIENCE
IS STENT THROMBOSIS REDUCED WITH DES WITH DEGRADABLE POLYMER?
STENT THROMBOSIS: INSIGHTS FROM OPTICAL COHERENCE THMOGRAPHY
APPROPRIATE TIMING FOR THE USE OF DAT WITH THE NEW GENERATION DES
PHARMACOTHERAPEUTIC CONSIDERATIONS FOR THE USE OF PRASUGREL AND TICAGRELOR TO REDUCE STENT THROMBOSIS

top of page